Fintel reports that on December 2, 2024, Goldman Sachs initiated coverage of Radius Recycling (NasdaqGS:RDUS) with a Neutral recommendation.
Analyst Price Forecast Suggests 12.51% Downside
As of May 22, 2024, the average one-year price target for Radius Recycling is $17.34/share. The forecasts range from a low of $17.17 to a high of $17.85. The average price target represents a decrease of 12.51% from its latest reported closing price of $19.82 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Radius Recycling is 3,537MM, an increase of 29.15%. The projected annual non-GAAP EPS is 5.14.
What is the Fund Sentiment?
There are 403 funds or institutions reporting positions in Radius Recycling. This is an decrease of 11 owner(s) or 2.66% in the last quarter. Average portfolio weight of all funds dedicated to RDUS is 0.07%, an increase of 9.03%. Total shares owned by institutions increased in the last three months by 3.91% to 27,333K shares. 
The put/call ratio of RDUS is 0.42, indicating a bullish outlook.
What are Other Shareholders Doing?
Ameriprise Financial holds 2,122K shares representing 7.62% ownership of the company. In its prior filing, the firm reported owning 1,847K shares , representing an increase of 12.96%. The firm decreased its portfolio allocation in RDUS by 75.83% over the last quarter.
Segall Bryant & Hamill holds 840K shares representing 3.02% ownership of the company. In its prior filing, the firm reported owning 905K shares , representing a decrease of 7.80%. The firm decreased its portfolio allocation in RDUS by 13.38% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 819K shares representing 2.94% ownership of the company. No change in the last quarter.
FDVLX - Fidelity Value Fund holds 685K shares representing 2.46% ownership of the company. No change in the last quarter.
IWM - iShares Russell 2000 ETF holds 680K shares representing 2.44% ownership of the company. In its prior filing, the firm reported owning 602K shares , representing an increase of 11.45%. The firm increased its portfolio allocation in RDUS by 18.29% over the last quarter.
Radius Health Background Information
(This description is provided by the company.)
Radius Health Inc. is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine and other therapeutics. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
